• breast cancer - triple negative
• es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
• es-BC - TNBC - NA - all population 5
• es-BC - TNBC - NA - PDL1 positive 1
• es-BC - Triple negatif (TNBC) - 1st line (L1)
• mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
• mBC - Triple negative (TNBC) - 1st Line (L1) 1
• mBC - TNBC - L1 - all population 7
• mBC - TNBC - L1 - PDL1 positive 4
• mBC-Triple negative (TNBC) - 2nd Line (L2) 3
• mBC - TNBC - L2 - all population 2
• mBC - TNBC - L2 - PDL1 positive 2

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus nab-paclitaxel
• atezolizumab plus paclitaxel
• pembrolizumab based treatment
• pembrolizumab plus SoC

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs placebo plus SoC

  All patients Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mBC - TNBC - L1 - PDL1 positive, pembrolizumab plus SoC vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;